EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Buprenorphine and its formulations: a comprehensive review

Salomon Poliwoda, Nazir Noor, Jack S Jenkins, Cain W Stark, Mattie Steib, Jamal Hasoon, Giustino Varrassi, Ivan Urits, Omar Viswanath, Adam M Kaye, Alan D Kaye

Health Psychology Research · 20.08.2022 · 10 (3) · 1

DOI: 10.52965/001c.37517 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Psychology Research, online erschienen am 20.08.2022. Verfasst von Salomon Poliwoda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Mount Sinai Medical Center. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Buprenorphine, a novel long-acting analgesic, was developed with the intention of two purposes: analgesia and opioid use disorder. Regarding its pharmacodynamics, it is a partial agonist at mu receptors, an inverse agonist at kappa receptors, and an antagonist at delta receptors. For the purpose of analgesia, three formulations of buprenorphine were developed: IV/IM injectable formulation (Buprenex®), transdermal patch formulation (Butrans®), and buccal film formulation (Belbuca®). Related to opioid dependence, the formulations developed were subcutaneous extended release (Sublocade®), subdermal implant (Probuphine®), and sublingual tablets (Subutex®). Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations.

Schlagwörter

Stichwörter der Autor:innen

Buprenoprhineanalgesicchronic painpartial agonistsubstance abuse

Autor:innen und Institutionen

  • Department of Anesthesiology, Mount Sinai Medical Center.
  • Ochsner-LSU Health Shreveport Medical School.
  • Medical College of Wisconsin, 8701 West Watertown Plank Road, Wauwatosa, WI 53226.
  • Louisiana State University Health Shreveport School of Medicine.
  • Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, Beth Israel Deaconess Medical Center.
  • Paolo Procacci Foundation Via Tacito 7, Rome, Italy.

Zitieren

APA

Poliwoda, S., Noor, N., Jenkins, J. S., Stark, C. W., Steib, M., Hasoon, J., Varrassi, G., Urits, I., Viswanath, O., Kaye, A. M., & Kaye, A. D. (2022). Buprenorphine and its formulations: a comprehensive review. Health Psychology Research, 10(3), 1. https://doi.org/10.52965/001c.37517

Vancouver

Poliwoda S, Noor N, Jenkins JS, Stark CW, Steib M, Hasoon J, et al. Buprenorphine and its formulations: a comprehensive review. Health Psychology Research. 2022;10(3):1. doi:10.52965/001c.37517

BibTeX
@article{Poliwoda2022,
  author = {Poliwoda, Salomon and Noor, Nazir and Jenkins, Jack S and Stark, Cain W and Steib, Mattie and Hasoon, Jamal and Varrassi, Giustino and Urits, Ivan and Viswanath, Omar and Kaye, Adam M and Kaye, Alan D},
  title = {Buprenorphine and its formulations: a comprehensive review},
  journal = {Health Psychology Research},
  year = {2022},
  volume = {10},
  number = {3},
  pages = {1},
  doi = {10.52965/001c.37517}
}
Kostenlos starten →